Title

Field evaluation of specificity and sensitivity of a standard SARS-CoV-2 antigen rapid diagnostic test: A prospective study at a teaching hospital in Northern Ghana

Authors

Alhassan Abdul-Mumin[1,2], Abdulai Abubakari[3], Faith Agbozo[4], Abass Abdul-Karim[5], Benjamin Demah Nuertey[2], Kareem Mumuni[2], Anna-Katharina Heuschen[6$], Lisa Hennig[6], Claudia M. Denkinger[7]*, Olaf Müller[6]*, Albrecht Jahn[6]*

1. University for Development Studies, School of Medicine, Department of Paediatrics and Child Health, Tamale, Ghana
2. Tamale Teaching Hospital, Tamale, Ghana
3. University for Development Studies, School of Public Health, Department of Global Health, Tamale, Ghana
4. University of Health and Allied Sciences, School of Public Health, Department of Family and Community Health, Hohoe, Ghana
5. Ghana Health Service, Zonal Public Health and Reference Laboratory, Tamale, Ghana
6. Institute for Global Health, University Hospital Heidelberg, Ruprecht-Karls-University Heidelberg
7. Department of Infectious Diseases, Division of Tropical Medicine, University Hospital Heidelberg, Ruprecht-Karls-University Heidelberg

*These authors contributed equally to the paper

$Corresponding author

Abstract

Background: The testing capacity for SARS-CoV-2 in Africa is rather limited. Antigen-

detection rapid diagnostic tests (Ag-RDTs) are a cheap and rapid alternative to reverse

transcriptase-polymerase chain reaction (RT-PCR) tests, but there is little data about their

performance under real life conditions in tropical countries.

Objective: To evaluate the performance of a standard Ag-RDT in a population of a major

hospital in northern Ghana.

Methods: Prospective, cross-sectional, blinded verification of the performance of the SD

Biosensor Standard Q SARS-CoV-2 Ag-RDT under real life conditions in 135 symptomatic

patients and 58 contacts of RT-PCR positives at Tamale Teaching Hospital in February 2021.

Nasopharyngeal samples were taken under standard conditions and tested against RT-PCR in

the hospital laboratory.

Results: 193 participants (median age 35 years, 109 male) were included into the study for

which both RT-PCR test and Ag-RDT results were available. A total of 42 (22%) were RT-

PCR positive. Of the 42 RT-PCR positives, 27 were Ag-RDT positive, resulting in a sensitivity

of 64% (95% CI 49-79). Sensitivity among symptomatic patients was 58% (95% CI 38-78).

123 were identified Ag-RDT negatives of the 151 RT-PCR negatives, resulting in a specificity

of 81% (95% CI 75-87).

Conclusions: SARS-CoV-2 Ag-RDTs appear to have a rather low sensitivity and particularly

a low specificity under real life conditions in Africa. The role of existing Ag-RDTs in countries

with high-temperature climates and limited resources still needs more data and discussion.

Background

The emergence of COVID-19 in China by the end of 2019 has led to the largest pandemic in recent human history (1, 2). It had initially been predicted, that Africa would become the worst affected global region, due to its weak health systems, prevailing poverty, and the existing high burden of infectious diseases (3, 4). However, by the end of 2020, only some 2% of the global number of cases and deaths were reported from the WHO African Region, but there have recently been signs for a resurgence of the number of cases (5).

There are various potential reasons for the low number of cases reported from sub-Saharan Africa (SSA). The likely main reasons are a much lower testing capacity in most countries of SSA and a much younger population associated with fewer symptomatic cases; however, other factors such as climate, which may affect transmission dynamics, the effects of early public health response measures, herd immunity due to cross reactions with other corona viruses or prevailing parasitic infections may also play a role (4). Findings from SARS-CoV-2 seroprevalence surveys support the growing evidence of under-reporting and a high proportion of asymptomatic and mild cases in SSA countries (6). In Zambia for example, a population-based survey has shown that the number of laboratory-confirmed SARS-CoV-2 cases are underestimating the real degree of community transmission at least 100-fold (7). However, SARS-CoV-2 serology results in SSA resulting from commercial tests validated outside Africa need to be interpreted with caution (8).

Testing is essential for the diagnosis of COVID-19 patients and to identify those persons who are infectious. Molecular assays to diagnose SARS-CoV-2 are considered the gold standard for detection of SARS-CoV-2 infection. They are typically based on RT-PCR to detect viral RNA and are highly sensitive and specific (9). However, they require a good laboratory infrastructure, trained staff, expensive equipment, and results are usually available only with

significant delay (10). Single use, lateral flow, antigen-detection rapid diagnostic tests (Ag-

RDTs) are a cheaper and easy to use alternative to RT-PCR tests. They are considered as a

useful supplement to RT-PCR testing, in particular as they mainly identify cases in the early

phase of disease and with high viral load and thus likely to be infective, and as they provide

results within 15 minutes (11, 12). An increasing number of Ag-RDTs has become authorized

by the US Food and Drug Administration (FDA) and other health authorities, which have been

shown to be highly specific, but not as sensitive as molecular tests (10). WHO recommends a

minimum sensitivity of 80% and a minimum specificity of 97% for SARS-CoV-2 Ag-RDTs

(10).

We here report the results of a field evaluation of a standard SARS-CoV-2 Ag-RDT

(SD Biosensor Standard Q) in Ghana which assesses whether the performance reported in

clinical studies in mostly high-resourced countries with moderate climates holds up in low-

resourced settings with high-temperature climates.

Methods

Study location and population

This study was conducted in the Tamale Teaching Hospital, situated in Tamale in the Northern

Region of Ghana. It serves as the only tertiary health care facility for the Northern Region

(where Tamale is located), Northeast, Savannah, Upper East and Upper West Regions as well

as parts of the Bono East and Oti Regions of Ghana. Together, the population of the catchment

area is about six million. The hospital also serves as the clinical training setting for students of

the *University for Development Studies*. Since the detection of the first case of COVID-19 in

Ghana in March 2020, the hospital has been at the forefront of the fight against the pandemic

in the northern sector of the country. It hosts the only treatment center for COVID-19 as well

as the zonal laboratory, where most samples taken from suspected COVID-19 cases are tested.

COVID-19 in Ghana

The first cases of COVID-19 in Ghana were recorded on March 12, 2020, while the first case

in Tamale has occurred about two weeks after this. By September 9, 2021, Ghana – with a

population of about 30 million - had a total of 123,874 reported SARS-CoV-2/COVID-19 cases

and 1098 reported deaths (13). The Northern Region has recorded 1,713 cases to date, with the

majority of these cases coming from the Tamale metropolis. A lockdown, mainly for Greater

Accra and some parts of the Ashanti Region, was imposed for two weeks in April 2020 to stem

the control of the virus spread. While the first epidemic wave lasted from March until

November 2020, a second wave is currently under way, driven mainly by new strains of the

virus with higher infectivity, and increasing rates of hospitalization due to severe symptoms

(13, 14). Ghana has a limited capacity to run RT-PCR tests, which has resulted in significant

delays in getting RT-PCR test results during the first and second waves of the pandemic.

Study design and participants

This study is a cross-sectional, blinded verification study of the performance of the Standard

Q SARS-CoV-2 Ag-RDT under real life conditions at the Tamale Teaching Hospital. From

February 15 to 20, 135 consecutive patients and 58 contacts were recruited. The patients were

eligible if they were referred by an attending physician because they exhibited signs suggestive

of COVID-19 (symptomatic), or if they were contacts of patients who tested positive for

COVID-19 by RT-PCR test. None of the asymptomatic participants reported back to hospital

with symptoms within 14 days after the sample collection.

The sample size of 200 was determined using the Cochrane (1977) formula for sample size

calculation.

Following verbal informed consent, clinical and demographic data were recorded from the

study participants on a standard questionnaire, including specific symptoms, age, and sex.

None of the participants declined for samples to be taken and to participate in the study.

Index test

The Ag-RDT evaluated was the STANDARD Q SARS-CoV-2 Ag Test (SD Biosensor, Inc.

Gyeonggi-do, Korea), which is distributed by Roche (15). The test was purchased in

Switzerland and transported to the Institute of Global Health in Heidelberg, Germany, using

standard procedures. From Heidelberg, the tests were sent to Tamale, Ghana, by air, again

using standard procedures for transport of laboratory materials. In Tamale, the test kits were

stored in a designated storage room at the Tamale Teaching Hospital at temperatures between

22°C and 27°C. Testing was done according to manufacturer's instructions for use. However,

both the COVID-19 isolation center and the general wards were not air-conditioned, and the

environmental temperature fluctuated between 24°C and 37°C. Most of the tests were done

during daytime when the temperature was highest.

Reference test

Reverse transcriptase-polymerase chain reaction (RT-PCR) was used as the reference test. The

RT-PCR samples were collected by health-care workers using nasopharyngeal swabs. At the

study laboratory, the samples were initially lysed to inactivate any viral agent, followed by

extraction of the viral RNA in separate biosafety class 2 cabinets. The next step involved the

mastermix preparation and template addition in separate hoods. The final stage was

amplification using AriaMx real-time PCR thermocycler. The reagent used was LightMix®

SarbecoV E-gene (manufacturer TIB MOLBIOL) which is the standard assay used in the

Public Health Reference Laboratory. The assay targets only the E-gene of SARS-CoV-2.

Further details and test properties can be found in the instructions for use (16). A Ct value of

<40 is interpreted as a positive and Ct values ≥40 as a negative test result for SARS-CoV-2.

<u>Sample collection and testing</u>

Samples were collected by a clinical team at the study hospital, consisting of physicians, nurses,

and biomedical laboratory scientists. Two nasopharyngeal samples were taken from the same

nostril by trained staff from each participant. One sample was tested immediately at the hospital

using the Standard Q SARS-CoV-2 Ag-RDT, with the result being interpreted according to the

manufacture`s guidelines and recorded on a specific paper form. The second sample was

transported in a viral transport medium to the zonal public health laboratory located within the

premises of the Teaching Hospital for extraction and RT-PCR testing.

<u>Statistical methods</u>

To determine sensitivity and specificity of the Standard Q SARS-CoV-2 Ag-RDT (with 95%

CIs), results were compared to RT-PCR results from the same participant, as per Altman (17).

A predefined subgroup analysis by symptoms presence was performed.

We used "R" version 4.0.3. (R Foundation for Statistical Computing, Vienna, Austria) to

generate all analyses and plots.

<u>Ethical aspects</u>

The evaluation protocol was approved by the Ethical Review Committee of the Tamale

Teaching Hospital. The data used for the evaluation were routine data from the hospital

services. Laboratory samples were anonymized and results could not be traced to individual

participants. All participants provided verbal informed consent and there were no refusals.

Results

A total of 198 participants were recruited for the study. For five participants, no RT-PCR results

were available. Thus, 193 participants were included into the study for which both RT-PCR

test and Ag-RDT results were available.

<u>Demographic characteristics</u>

The median age was 35 years (range: 5 months to 93 years). 109 participants were male, 84

were female.

<u>Clinical characteristics</u>

Table 1 shows the clinical characteristics of the study participants. 135 (70%) were

symptomatic; 58 (30%) were asymptomatic. Cough (60%), fever (34%), general weakness

(36%), rhinitis (36%) and headache (36%) were the main symptoms recorded. Ageusia and

anosmia were recognized in only 16% and 19% of study participants respectively. Non-

communicable diseases (NCDs) that are associated with severe COVID-19 were very rare (one

case each of Diabetes mellitus, hypertension and cardiovascular disease), and none of the study

participants was on medication for a chronic disease.

Table 1: Clinical characteristics of study participants in Tamale Teaching Hospital, Ghana

	Diagnosis	number	proportion
187			
188	Asymptomatic	58/193	30%
189	Symptomatic	135/193	70%
190	--		
191	Cough	81/135	60%
192	Fever	46/135	34%
193	Weakness	49/135	36%
194	Rhinitis	48/135	36%
195	Headache	49/135	36%
196	Sore throat	24/135	18%
197	Dyspnea	22/135	16%
198	Diarrhea	11/135	8%
199	Nausea/vomiting	11/135	8%
200	Pain	38/135	28%
201	*joint pain*	7/135	5%
202	*muscle pain*	15/135	11%
203	*chest pain*	16/135	12%
204	*abdominal pain*	24/135	18%
205	Anosmia	25/135	19%
206	Ageusia	21/135	16%

NCDs   3/135   2%

<u>Test results</u>

Table 2 and 3 show the results. A total of 42 (22%) study participants were RT-PCR positive,

and 151 (78%) were RT-PCR negative. Of the 42 RT-PCR positives, 27 were Ag-RDT

positive, resulting in a sensitivity of 64% (95% CI 49-79). 123 were identified Ag-RDT

negative of the 151 RT-PCR negatives, resulting in a specificity of 81% (95% CI 75-87). The

positive predictive value of the Ag-RDT in this population was 49% (95% CI 36-62) and the

negative predictive value 89% (95% CI 84-94). The positive predictive accuracy (PPA) of the

test was 28% and negative predictive accuracy (NPA) was 95%. Among the asymptomatic

participants, there were 18 RT-PCR positives (31%) and 13 (72%) (95% CI 51-93) were

detected by Ag-RDT. Only considering the symptomatic participants (24 RT-PCR positives,

18%), the sensitivity was 58% (95% CI 38-78). Regarding the cycle threshold (Ct) values of

our participants who were PCR positive (40/42), none was <25; 8 (20%) had values between

25 and <30; 29 (72.5%) were between 30 and <35; and 3 (7.5%) were between 35 and <40.

<u>Table 2:</u> SARS-CoV-2 Ag-RDT test results in comparison to RT-PCR results in Tamale

Teaching Hospital, Ghana

Ag-RDT result	RT-PCR result		Total
	Positive	Negative	
Positive	27	28	55
Negative	15	123	138
Total	42	151	193

231 <u>Table 3:</u> Subgroup analysis results of true/false positives and negatives in Tamale Teaching

232 Hospital, Ghana

	n	TP	FP	TN	FN	PPV	NPV	PPA	NPA	Sensitivity (95%CI)	Specificity (95%CI)
Overall	193	14%	15%	64%	8%	48%	89%	28%	95%	64% (95%CI 49-79)	81% (95%CI 75-87)
Symptomatic	135	10%	19%	64%	7%	34%	90%	22%	94%	58% (95%CI 38-78)	77% (95%CI 69-85)
Asymptomatic	58	22%	5%	64%	9%	81%	87%	54%	96%	72% (95%CI 51-93)	93% (95%CI 85-100)

234 TP=true positives, FP=false positives, TN=true negatives, FN=false negatives, PPV=positive predictive value,

235 NPV=negative predictive value, PPA=positive predictive accuracy, NPA=negative predictive accuracy

Discussion

Our study demonstrates a limited sensitivity (64%) and very low specificity (81%) for a WHO

approved SARS-CoV-2 Ag-RDT, which is much below the performance demonstrated in

systematic reviews (73,8%) and 99,7% respectively)(12) and even more so with the

manufacturers data (sensitivity 76,6% and specificity 97,6%)(18).

Much of the data generated by the Standard Q Ag-RDT stem from high resource

settings with temperate climates. There are limited data on evaluations of SARS-CoV-2 Ag-

RDT available until very recently from lower-resourced settings with hotter climates (19). A

study in Cameroon compared results from the SD Biosensor Standard Q SARS-CoV-2 Ag-

RDT with RT-PCR results in asymptomatic and symptomatic adult participants from eight

hospitals and demonstrated an overall sensitivity of 59% (95% CI 53-65), with the sensitivity

increasing to 69% (95% CI 62-75) when only symptomatic participants were considered (20).

Another study in Uganda compared results from another SARS-CoV-2 Ag-RDT with RT-PCR

results in adult hospital patients and controls and demonstrated a sensitivity of 70% (95% CI

60-79) (21).

The sensitivity in our study (64% overall and 58% in symptomatic participants) is

comparable to this data from Uganda and Cameroon. Interestingly, the sensitivity in

asymptomatic participants in our study was higher than in symptomatic participants, but this

did not reach statistical significance. A potential explanation could be that more of the

asymptomatic patients were captured early in the disease when the viral load is high. The higher

sensitivity in asymptomatic patients speaks more for participants related aspects affecting the

sensitivity than operational or environmental factors, as those would be expected to affect

performance in symptomatic and asymptomatic participants equally (22).

Specificity in our study (81%) is lower than that demonstrated in both Uganda and

Cameroon (92%) (20, 21) and shows that under study conditions in SSA countries a much

lower specificity than the WHO requested minimum specificity of 97% has to be expected.

Possible explanations for the lower specificity in our study could be cross-reacting antibodies

from previous infections or the environmental temperatures (24°-37°C) during the study period

in the rooms (the general wards and the COVID-19 isolation center) where the tests were

carried out. The Ct values for our patients, who were tested RT-PCR positive, were generally

high. As reported in the results, none of the participants had Ct values < 25 and the majority of

the values were between 30 to <35 (72.5%). This could have affected the performance of the

RDTs as higher Ct values correspond with lower viral load and studies have shown that the

performance of RDTs fall with increasing Ct values (12, 23). In addition, most testing occurred

during the day when temperatures were high although direct sunlight was avoided. The

manufacturer recommends a temperature of maximum 30°C and others have demonstrated that

high temperatures above the manufacturer recommended targets negatively affect the test

performance (22). While the study by Haage et al. demonstrated an effect of high temperatures

primarily on sensitivity, others have shared the experience that it also substantially affects

specificity (Denkinger personal communication). One way to minimize the effects of high

temperatures on the test accuracy in these settings would be to conduct the tests in the mornings

and evenings when the environmental temperature will be relatively lower. However, care must

be taken not to negate the advantage of the RDT test, which is to provide rapid results to aid

clinical decision making. Another important factor could be the high prevalence of other

endemic infectious diseases, or others as yet unknown factors (4, 20).

Having Ag-RDTs with high specificity and sensitivity will be a key element for

controlling the pandemic in settings like northern Ghana in particular as well as Ghana and

SSA in general. This is due to the fact that the turnaround time for the gold standard test (PCR)

was very long in both the first and second wave of the pandemic due to limited testing capacity.

As a result, clinical decision making was delayed and increased the risk of further transmission.

RDTs with their quick turnaround time could facilitate clinical decision making and contact

screening of confirmed COVID-19 cases. The high negative predictive accuracy for the Ag-

RDTs used in this study makes it a valuable tool for these purposes but all positive tests will

require confirmation with RT-PCR test (24).

The limitations of this study are firstly that it was done in one center of one country

only, thus limiting generalizability. Secondly, the overall sample size was small and further

subgroup analyses to better understand the data were not possible. Thirdly, the temperature at

time of testing was not recorded thus limiting a differentiated understanding of the impact of

temperature. Another limitation is that the study did not include the duration between the onset

of symptoms and the timing of the testing for the symptomatic participants. And while it is a

limitation that the tests were not performed in manufacturer recommended temperature range,

the strength of this study is, that it has been done under real life conditions in a high-

temperature, limited resource country.

Conclusion

This field evaluation of a standard SARS-CoV-2 Ag-RDT shows a rather low sensitivity and specificity. Given these findings, further studies are needed to assess the role of existing Ag-RDTs in high-temperature climates in Africa and around the world, where easy-to-use tests are urgently needed as RT-PCR testing is not widely available.

Contributors

CMD, AJ, and AAM designed the study, OM wrote the first paper draft, AAM coordinated the field work, all authors contributed to the content of the paper.

Declaration of interests

We declare no conflict of interests.

Funding

The study has received funding from the *Gesellschaft für Internationale Zusammenarbeit* (GIZ) in Germany.

Acknowledgements

We thank the Covid-19 team of the *Tamale Teaching Hospital* for assisting with the sample collection, Dr. Kingsley Bimpong and Dr. Hadi Salawudini for assisting with data entry, and

the staff of the *Zonal Public Health and Reference Laboratory*, Tamale, for assisting with the

RT-PCR testing.

References

1.   Müller O, Lu G, Jahn A, Razum O. COVID-19 Control: Can Germany Learn From

China? Int J Health Policy Manag. 2020;9(10):432-5.

2.   Lu G, Razum O, Jahn A, Zhang Y, Sutton B, Sridhar D, et al. COVID-19 in Germany

and China: mitigation versus elimination strategy. Glob Health Action. 2021;14(1):1875601.

3.   Massinga Loembé M, Tshangela A, Salyer SJ, Varma JK, Ouma AEO, Nkengasong

JN. COVID-19 in Africa: the spread and response. Nat Med. 2020;26(7):999-1003.

4.   Maeda JM, Nkengasong JN. The puzzle of the COVID-19 pandemic in Africa.

Science. 2021;371(6524):27-8.

5.   Impouma B, Wolfe CM, Mboussou F, Farham B, Saturday T, Pervilhac C, et al.

Monitoring and Evaluation of COVID-19 response in the WHO African Region: challenges

and lessons learned. Epidemiol Infect. 2021:1-14.

6.   Usuf E, Roca A. Seroprevalence surveys in sub-Saharan Africa: what do they tell us?

Lancet Glob Health. 2021.

7.   Mulenga LB, Hines JZ, Fwoloshi S, Chirwa L, Siwingwa M, Yingst S, et al.

Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster

sample survey. The Lancet Global Health. 2021.

8.   Nkuba Ndaye A, Hoxha A, Madinga J, Mariën J, Peeters M, Leendertz FH, et al.

Challenges in interpreting SARS-CoV-2 serological results in African countries. The Lancet

Global Health. 2021;9(5):e588-e9.

9.   Tsang NNY, So HC, Ng KY, Cowling BJ, Leung GM, Ip DKM. Diagnostic

performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a

systematic review and meta-analysis. Lancet Infect Dis. 2021.

10.   Peeling RW, Olliaro PL, Boeras DI, Fongwen N. Scaling up COVID-19 rapid antigen

tests: promises and challenges. Lancet Infect Dis. 2021.

11.   Dinnes J, Deeks JJ, Adriano A, Berhane S, Davenport C, Dittrich S, et al. Rapid,

point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection.

Cochrane Database Syst Rev. 2020;8(8):Cd013705.

12.   Brümmer LE, Katzenschlager S, Gaeddert M, Erdmann C, Schmitz S, Bota M, et al.

Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review

and meta-analysis. PLOS Medicine. 2021;18(8):e1003735.

13.   SITUATION UPDATE, COVID-19 OUTBREAK IN GHANA [Internet]. 2021 [cited

20/05/2021]. Available from: https://www.ghanahealthservice.org/covid19/archive.php.

14.   WHO afro. New COVID-19 variants fuelling Africa's second wave2021. Available

from: https://www.afro.who.int/news/new-covid-19-variants-fuelling-africas-second-wave.

15.   Roche Group. Roche SARS-CoV-2 Rapid Antigen Test receives special approval for

at-home patient self-testing using nasal swabs in Germany 2021 [Available from:

https://www.roche.com/de/media/releases/med-cor-2021-02-26c.htm.

16.   MOLBIOL T. Instructions For Use: LightMix® SarbecoV E-gene plus EAV

control2020. Available from: https://www.roche-as.es/lm_pdf/MDx_40-0776_96_Sarbeco-E-

gene_V200204_09164154001%20(1).pdf.

17.   Altman DG, Bland JM. Diagnostic tests. 1: Sensitivity and specificity. Bmj.

1994;308(6943):1552.

18.   WHO. Veri-Q PCR 316 Coronavirus disease 2019(COVID-19) Detection Kit nCoV-

QS2021. Available from:

https://extranet.who.int/pqweb/sites/default/files/documents/eul_0495_188_00_nCoV-

QS_EN_IFU_v4.pdf.

19.   Jacobs J, Kühne V, Lunguya O, Affolabi D, Hardy L, Vandenberg O. Implementing

COVID-19 (SARS-CoV-2) Rapid Diagnostic Tests in Sub-Saharan Africa: A Review. Front

Med (Lausanne). 2020;7:557797.

20.   Boum Y, Bebell LM, Bisseck A-CZ-K. Africa needs local solutions to face the

COVID-19 pandemic. The Lancet. 2021;397(10281):1238-40.

21.   Nalumansi A, Lutalo T, Kayiwa J, Watera C, Balinandi S, Kiconco J, et al. Field

evaluation of the performance of a SARS-CoV-2 antigen rapid diagnostic test in Uganda

using nasopharyngeal samples. Int J Infect Dis. 2021;104:282-6.

22.   Haage V, Ferreira de Oliveira-Filho E, Moreira-Soto A, Kühne A, Fischer C, Sacks

JA, et al. Impaired performance of SARS-CoV-2 antigen-detecting rapid diagnostic tests at

elevated and low temperatures. Journal of Clinical Virology. 2021;138:104796.

23.   Peña M, Ampuero M, Garcés C, Gaggero A, García P, Velasquez MS, et al.

Performance of SARS-CoV-2 rapid antigen test compared with real-time RT-PCR in

asymptomatic individuals. Int J Infect Dis. 2021;107:201-4.

24.   Prince JR LD. Sensitivity, Specificity, and Predictive Accuracy as Measures of

Efficacy of Diagnostic Tests. Annals of Saudi Medicine. 1981;1:13-8.